Home > Dermatology > Risankizumab improves patient-reported outcomes in moderate to severe psoriasis

Risankizumab improves patient-reported outcomes in moderate to severe psoriasis

Journal
JAMA Dermatology
Reuters Health - 22/10/2020 - Risankizumab treatment significantly improves symptoms, health-related quality of life and mental health among patients with moderate to severe psoriasis, according to findings from two randomized clinical trials. "These findings may further raise standards for treatments and provide promising outcomes for patients suffering from moderate to severe chronic plaque psoriasis," researchers write in JAMA Dermatology. Dr. Kenneth B. Gordon of the Medical College of Wisconsin, in Milwaukee, and colleagues combined data from the UltIMMa-1 and -2 trials, which compared risankizumab versus ustekinumab or placebo in patients with moderate to severe psoriasis, to evaluate patient-reported outcomes that were included in the studies as secondary endpoints. Risankizumab, an interleukin (IL)-23 inhibitor, is approved in the U.S. and Europe. After treatment, patients in the risankizumab group had significantly lower Psoriasis Symptom Scal...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on